Hepatic stellate cells are the liver's principal scar-forming cells, and they sit at the center of almost every model of liver fibrosis. In a healthy liver they are quiet, vitamin‑A‑storing cells; after injury they transform into collagen-producing myofibroblasts that drive fibrosis, cirrhosis, and much of the tissue remodeling seen in chronic liver disease. This guide explains what hepatic stellate cells do, how they switch into their fibrogenic state, and how the two most widely used cell-line models — human LX-2 and rat HSC-T6 — compare when you set up an experiment.
What Are Hepatic Stellate Cells?
Hepatic stellate cells (HSCs) are a specialized, minor population of liver cells that reside in the space of Disse — the narrow perisinusoidal gap between the sinusoidal endothelium and the hepatocytes. They were first described by Kupffer and later characterized by Toshio Ito, which is why they are still commonly called Ito cells (and, in older literature, fat-storing cells or lipocytes).
Their defining feature in the resting, or quiescent, state is retinoid storage: quiescent stellate cells are the body's principal reservoir of vitamin A, holding it as retinyl esters in characteristic cytoplasmic lipid droplets. Beyond storage, they help regulate sinusoidal blood flow, contribute growth factors important to liver development and regeneration, and participate in the liver's inflammatory response.1
Quiescent vs Activated: The Switch That Drives Liver Fibrosis
Chronic liver injury — from viral hepatitis, alcohol, or metabolic (MASH/NASH) disease — triggers hepatic stellate cell activation. In this process the quiescent, vitamin‑A‑storing cell transdifferentiates into a proliferative, fibrogenic myofibroblast.2 As they activate, the cells lose their vitamin A droplets, up-regulate alpha smooth muscle actin (α-SMA), and begin secreting large amounts of extracellular matrix proteins, above all type I collagen, together with inhibitors of matrix degradation.3
Because activated stellate cells are the main effector cells of hepatic fibrogenesis and the principal source of scar-forming myofibroblasts, they are the central target of most antifibrotic drug research.3 Importantly, activation is not a one-way street: liver fibrosis can regress when the underlying injury is removed, as activated stellate cells are cleared through apoptosis, senescence, or reversion toward an inactivated state.2
Why Researchers Use HSC Cell Line Models
Freshly isolated primary hepatic stellate cells are the gold standard for physiology, but they are difficult to obtain in quantity, vary from donor to donor, and begin to activate spontaneously once plated on standard tissue-culture plastic — a property that is itself exploited as an in‑vitro activation model, but which makes reproducible, long-term work hard. Immortalized hepatic stellate cell lines were developed to solve this: they grow indefinitely, behave consistently between passages, and retain many of the key features of primary cells, which makes them practical tools for studying fibrosis pathways, retinoid metabolism, and candidate antifibrotic compounds.
Two lines dominate the literature. LX-2 is the reference human model; HSC-T6 is a widely used rat model. Both are available from BioHippo's cell lines catalog.
LX-2 vs HSC-T6: Choosing a Hepatic Stellate Cell Line
The right line depends on the species you need, the pathway you are studying, and whether you plan to transfect the cells. LX-2 was generated by spontaneous immortalization of human stellate cells under low-serum conditions. It expresses the stellate-cell markers α-SMA, vimentin, and glial fibrillary acidic protein (GFAP), together with key fibrosis receptors such as β-PDGF receptor and discoidin domain receptor 2, and its gene-expression profile matches primary human stellate cells by roughly 98.7%. Two practical advantages set LX-2 apart: it remains viable in serum-free medium and it is highly transfectable, which makes it well suited to gene-function and reporter studies.4
HSC-T6 is an immortalized rat stellate cell line established as a model for hepatic retinoid metabolism. Like activated primary stellate cells it expresses myogenic and neural-crest cytoskeletal filaments, and it retains a faithful retinoid phenotype — it takes up and esterifies retinol, expresses all six retinoid nuclear receptors (RARα/β/γ and RXRα/β/γ), and expresses cellular retinol-binding protein type I. This makes HSC-T6 a strong choice for vitamin A and retinoid-signaling work in a rodent background.5
| Feature | LX-2 | HSC-T6 |
|---|---|---|
| Species | Human | Rat |
| Origin / immortalization | Spontaneous immortalization in low serum | Immortalized rat hepatic stellate cell line |
| Key markers | α-SMA, vimentin, GFAP; β-PDGF-R, DDR2 | Myogenic & neural-crest cytoskeletal filaments |
| Retinoid phenotype | Retinoid phenotype typical of stellate cells | Takes up/esterifies retinol; all 6 retinoid nuclear receptors; CRBP-I positive |
| Serum-free viability | Yes (a distinguishing advantage) | Not a defined feature |
| Transfectability | High | Not a defined feature |
| Similarity to primary HSCs | ~98.7% gene-expression match | Same retinoid phenotype as primary cells |
| Best suited to | Human fibrosis pathways, antifibrotic screening, transfection studies | Retinoid / vitamin A metabolism, rat fibrosis models |
| BioHippo catalog no. | BHC11101263 | BHC11101266 |
Working With Hepatic Stellate Cells in Culture
Both LX-2 and HSC-T6 are adherent lines and grow as flat, epithelial-like monolayers on standard tissue-culture plasticware. A few points are worth keeping in mind when you design experiments with hepatic stellate cells:
- Baseline activation state. Immortalized lines are already partly activated and express α-SMA, so they model the activated rather than the fully quiescent phenotype. Plan controls accordingly if your question depends on the quiescent state.
- Substrate stiffness matters. Because stellate cells sense matrix stiffness, cells grown on rigid plastic behave more like myofibroblasts than cells on soft matrices. Where physiological relevance is important, consider soft-substrate or 3D formats.
- Serum-free options. LX-2 tolerates serum-free medium, which is useful when serum factors would confound a signaling or secretion readout.
- Transfection. For knockdown, overexpression, or reporter assays in a human background, LX-2's high transfectability is a practical advantage.
Frequently Asked Questions
What are hepatic stellate cells also called?
They are most often called Ito cells, after Toshio Ito, who characterized them. Older names include fat-storing cells and lipocytes, reflecting their vitamin‑A‑rich lipid droplets.
What do hepatic stellate cells do?
In a healthy liver they store most of the body's vitamin A and help regulate blood flow. After liver injury they activate into myofibroblasts and produce the collagen-rich scar tissue that defines liver fibrosis.
Are hepatic stellate cells the same as myofibroblasts?
Not exactly. A quiescent stellate cell is a distinct, vitamin‑A‑storing cell. It becomes a myofibroblast-like cell only after activation, so activated stellate cells are the main source of liver myofibroblasts rather than being identical to them from the start.
What markers identify activated hepatic stellate cells?
Alpha smooth muscle actin (α-SMA) is the classic activation marker. Stellate cells also express vimentin, GFAP, and β-PDGF receptor, which are commonly used alongside α-SMA to identify and study them.
What is the difference between LX-2 and HSC-T6 cells?
LX-2 is a human line best suited to human fibrosis pathways and transfection-based studies, and it grows in serum-free medium. HSC-T6 is a rat line especially useful for retinoid and vitamin A metabolism research. Species and application usually decide the choice.
Get Started
BioHippo stocks both hepatic stellate cell lines discussed here — the human LX-2 line and the rat HSC-T6 line — alongside a broader range of liver and other cell lines. For help matching a model to your fibrosis or retinoid study, request a quote and our team can advise.
References
- Kamm DR, McCommis KS. Hepatic stellate cells in physiology and pathology. J Physiol. 2022;600(8):1825–1837. doi:10.1113/JP281061
- Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol. 2017;14(7):397–411. doi:10.1038/nrgastro.2017.38
- Akkız H, Gieseler RK, Canbay A. Liver Fibrosis: From Basic Science towards Clinical Progress, Focusing on the Central Role of Hepatic Stellate Cells. Int J Mol Sci. 2024;25(14):7873. doi:10.3390/ijms25147873
- Xu L, Hui AY, Albanis E, et al. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut. 2005;54(1):142–151. doi:10.1136/gut.2004.042127
- Vogel S, Piantedosi R, Frank J, et al. An immortalized rat liver stellate cell line (HSC-T6): a new cell model for the study of retinoid metabolism in vitro. J Lipid Res. 2000;41(6):882–893. doi:10.1016/S0022-2275(20)32030-7
Figures 1–3 are illustrative summaries of characteristics reported in the cited literature, prepared for this guide; they do not present experimental data. Based on peer-reviewed articles retrieved from PubMed. Cell lines are sold for research use only.
